Maxcyte (MXCT) Accumulated Depreciation & Amortization (2020 - 2025)
Maxcyte (MXCT) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with -$5.0 million as the latest value for Q4 2024.
- On a quarterly basis, Accumulated Depreciation & Amortization rose 76.37% to -$5.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$5.0 million, a 76.37% increase, with the full-year FY2024 number at -$5.0 million, up 76.37% from a year prior.
- Accumulated Depreciation & Amortization was -$5.0 million for Q4 2024 at Maxcyte, up from -$6.2 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of -$2.6 million in Q4 2020 to a low of -$22.5 million in Q1 2023.
- A 5-year average of -$12.7 million and a median of -$13.5 million in 2022 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: plummeted 121.14% in 2023, then skyrocketed 76.37% in 2024.
- Maxcyte's Accumulated Depreciation & Amortization stood at -$2.6 million in 2020, then crashed by 115.07% to -$5.6 million in 2021, then plummeted by 71.52% to -$9.5 million in 2022, then tumbled by 121.14% to -$21.1 million in 2023, then surged by 76.37% to -$5.0 million in 2024.
- Per Business Quant, the three most recent readings for MXCT's Accumulated Depreciation & Amortization are -$5.0 million (Q4 2024), -$6.2 million (Q3 2024), and -$17.4 million (Q2 2024).